Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: Granulysin (cytolytic molecules of cytotoxic T lymphocytes and natural killer cells) is synthesized as cytosolic 9-kDa and secretary 15-kDa isoforms. We evaluated the prognostic significance of the pretreatment serum level of 15-kDa granulysin in patients with diffuse large B cell lymphoma (DLBCL). Patients and Methods: A retrospective analysis was conducted on 88 DLBCL patients treated homogeneously with standard chemotherapy. The granulysin level was quantified in pretreatment samples. Results: The granulysin level in DLBCL patients was significantly lower than that in healthy controls (522 ± 496 vs. 1,945 ± 1,696 pg/ml; p < 0.0001), and the level in patients who experienced recurrence within 3 years was significantly lower than that of patients without recurrence (305 ± 337 vs. 720 ± 607 pg/ml; p = 0.001). Patients with granulysin levels higher than the median level showed significantly longer progression-free and overall survival according to univariate analysis (p = 0.031 and p = 0.014, respectively). In multivariate analysis, the granulysin level was an independently significant prognostic factor of overall survival (p = 0.018; hazard ratio, 0.521; 95% confidence interval, 0.188-0.841). Conclusions: Pretreatment serum level of 15-kDa granulysin may be a valuable prognostic marker in DLBCL patients treated with standard chemotherapy.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalActa Haematologica
Volume126
Issue number2
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Serum
Recurrence
Drug Therapy
Cytotoxic T-Lymphocytes
Natural Killer Cells
Disease-Free Survival
Protein Isoforms
Multivariate Analysis
Confidence Intervals
Survival

Keywords

  • Chemotherapy
  • Diffuse large B cell lymphoma
  • Granulysin

ASJC Scopus subject areas

  • Hematology

Cite this

@article{fd55d883ee0a41da85e9aabe34d5cc03,
title = "Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma",
abstract = "Aim: Granulysin (cytolytic molecules of cytotoxic T lymphocytes and natural killer cells) is synthesized as cytosolic 9-kDa and secretary 15-kDa isoforms. We evaluated the prognostic significance of the pretreatment serum level of 15-kDa granulysin in patients with diffuse large B cell lymphoma (DLBCL). Patients and Methods: A retrospective analysis was conducted on 88 DLBCL patients treated homogeneously with standard chemotherapy. The granulysin level was quantified in pretreatment samples. Results: The granulysin level in DLBCL patients was significantly lower than that in healthy controls (522 ± 496 vs. 1,945 ± 1,696 pg/ml; p < 0.0001), and the level in patients who experienced recurrence within 3 years was significantly lower than that of patients without recurrence (305 ± 337 vs. 720 ± 607 pg/ml; p = 0.001). Patients with granulysin levels higher than the median level showed significantly longer progression-free and overall survival according to univariate analysis (p = 0.031 and p = 0.014, respectively). In multivariate analysis, the granulysin level was an independently significant prognostic factor of overall survival (p = 0.018; hazard ratio, 0.521; 95{\%} confidence interval, 0.188-0.841). Conclusions: Pretreatment serum level of 15-kDa granulysin may be a valuable prognostic marker in DLBCL patients treated with standard chemotherapy.",
keywords = "Chemotherapy, Diffuse large B cell lymphoma, Granulysin",
author = "Yong Park and Choi, {Yoon Ji} and Park, {Se Jong} and Lee, {Se Ryeon} and Sung, {Hwa Jung} and Park, {Kyong Hwa} and Kim, {Soek Jin} and Choi, {Chul Won} and Kwang-Yoon Jung and Kim, {Byung Soo}",
year = "2011",
month = "8",
day = "1",
doi = "10.1159/000327255",
language = "English",
volume = "126",
pages = "79--86",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma

AU - Park, Yong

AU - Choi, Yoon Ji

AU - Park, Se Jong

AU - Lee, Se Ryeon

AU - Sung, Hwa Jung

AU - Park, Kyong Hwa

AU - Kim, Soek Jin

AU - Choi, Chul Won

AU - Jung, Kwang-Yoon

AU - Kim, Byung Soo

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Aim: Granulysin (cytolytic molecules of cytotoxic T lymphocytes and natural killer cells) is synthesized as cytosolic 9-kDa and secretary 15-kDa isoforms. We evaluated the prognostic significance of the pretreatment serum level of 15-kDa granulysin in patients with diffuse large B cell lymphoma (DLBCL). Patients and Methods: A retrospective analysis was conducted on 88 DLBCL patients treated homogeneously with standard chemotherapy. The granulysin level was quantified in pretreatment samples. Results: The granulysin level in DLBCL patients was significantly lower than that in healthy controls (522 ± 496 vs. 1,945 ± 1,696 pg/ml; p < 0.0001), and the level in patients who experienced recurrence within 3 years was significantly lower than that of patients without recurrence (305 ± 337 vs. 720 ± 607 pg/ml; p = 0.001). Patients with granulysin levels higher than the median level showed significantly longer progression-free and overall survival according to univariate analysis (p = 0.031 and p = 0.014, respectively). In multivariate analysis, the granulysin level was an independently significant prognostic factor of overall survival (p = 0.018; hazard ratio, 0.521; 95% confidence interval, 0.188-0.841). Conclusions: Pretreatment serum level of 15-kDa granulysin may be a valuable prognostic marker in DLBCL patients treated with standard chemotherapy.

AB - Aim: Granulysin (cytolytic molecules of cytotoxic T lymphocytes and natural killer cells) is synthesized as cytosolic 9-kDa and secretary 15-kDa isoforms. We evaluated the prognostic significance of the pretreatment serum level of 15-kDa granulysin in patients with diffuse large B cell lymphoma (DLBCL). Patients and Methods: A retrospective analysis was conducted on 88 DLBCL patients treated homogeneously with standard chemotherapy. The granulysin level was quantified in pretreatment samples. Results: The granulysin level in DLBCL patients was significantly lower than that in healthy controls (522 ± 496 vs. 1,945 ± 1,696 pg/ml; p < 0.0001), and the level in patients who experienced recurrence within 3 years was significantly lower than that of patients without recurrence (305 ± 337 vs. 720 ± 607 pg/ml; p = 0.001). Patients with granulysin levels higher than the median level showed significantly longer progression-free and overall survival according to univariate analysis (p = 0.031 and p = 0.014, respectively). In multivariate analysis, the granulysin level was an independently significant prognostic factor of overall survival (p = 0.018; hazard ratio, 0.521; 95% confidence interval, 0.188-0.841). Conclusions: Pretreatment serum level of 15-kDa granulysin may be a valuable prognostic marker in DLBCL patients treated with standard chemotherapy.

KW - Chemotherapy

KW - Diffuse large B cell lymphoma

KW - Granulysin

UR - http://www.scopus.com/inward/record.url?scp=79955389896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955389896&partnerID=8YFLogxK

U2 - 10.1159/000327255

DO - 10.1159/000327255

M3 - Article

C2 - 21540579

AN - SCOPUS:79955389896

VL - 126

SP - 79

EP - 86

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2

ER -